This site is intended for healthcare professionals
Micrograph of bone marrow rendered in pinks and purples

Find disease awareness content and relevant supporting materials

    Learning Zone CME Events News Trials Guidelines Journals
    Filter results
    Sort by:
    Relevance
    to
    Journals
    Journal
    01/02/17

    Vernakalant is superior to ibutilide for achieving sinus rhythm in patients with recent-onset atrial fibrillation: a randomized controlled trial at the emergency department.

    The aim of our study was to compare the time to conversion and the conversion rate within 90 min in patients with recent-onset atrial fibrillation treated with vernakalant or ibutilide.

    • Source: Europace
    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    31/03/16

    Results from study of Brinavess (vernakalant IV) shows benefits in atrial fibrillation- Cardiome Pharma

    Cardiome Pharma has announced the publication of results from an open label, single-center, randomized controlled study conducted by independent researchers...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    24/08/17

    FDA does not accept NDA application for Brinavess (vernakalant hydrochloride, IV) to treat atrial fibrillation.- Cardiome Pharma

    Cardiome Pharma Corp. announced that it has received a response from the FDA regarding the regulatory path for Brinavess (vernakalant...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    26/06/19

    Brinavess refiled with FDA for recent onset atrial fibrillation

    Correvio Pharma has resubmitted a New Drug Application (NDA) to the US FDA seeking approval for Brinavess (vernakalant hydrochloride, IV),...

    Journals
    Journal
    01/11/19

    Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials

    This study evaluates the efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP). It demonstrates significant improvements in nasal polyp size, sinus opacification, and symptom severity.

    • Source: The Lancet
    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    27/09/12

    Merck returns all rights to vernakalant to Cardiome Pharma for Atrial Fibrillation

    Merck & Co has returned the global marketing and development rights to Cardiome Pharma Corporation for both the intravenous and...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    06/03/16

    New data from CLEAR study shows Cosentyx (secukinumab) remains superior to Stelara (ustekinumab) in achieving sustained skin clearance in psoriasis patients- Novartis

    Novartis announced new late-breaking data from the head-to-head CLEAR study, demonstrating that Cosentyx (secukinumab) remains superior to Stelara (ustekinumab) in...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    23/03/13

    Study shows RoActemra/Actemra (Genetech/Roche) superior to Humira in achieving remission in Rheumatoid Arthritis patients

    New data confirms RoActemra/Actemra (tocilizumab), from Genetech/Roche, is superior to Humira (adalimumab) in achieving disease remission in Rheumatoid Arthritis patients...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    31/03/25

    FDA Issues Response for Cardamyst

    FDA issues complete response letter for Cardamyst nasal spray for PSVT conversion. Milestone Pharma's update.

    Blue test tubes arranged in a line, disappearing into the background
    News
    20/12/21

    Bimekizumab superior to Cosentyx in achieving complete psoriasis skin clearance. UCB

    UCB announced positive results from the Phase IIIb BE RADIANT study, a direct comparison of the investigational IL-17A and IL-17F inhibitor, bimekizumab, to the IL-17A inhibitor, Cosentyx (secukinumab) in the treatment of adult patients with moderate-to-severe plaque psoriasis.

    See more